Precision radiation may spare brain function in lung cancer patients
NCT ID NCT04516070
First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 2 times
Summary
This study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this targeted treatment. The goal is to see if this approach causes fewer side effects while still controlling the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
55 people
The number who actually took part.
- Started
-
Aug 2020
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must have Eastern Cooperative Oncology Group (ECOG) =\< 3 * All patients must have histologic evidence suggesting small cell lung cancer. Histologic confirmation may be from the primary tumor site, or from another metastatic site (systemic lymph node, etc.). Cytology-alone is not an acceptable method of diagnosis. * Patient has 10 or less brain metastases on contrast-enhanced brain MRI scan obtained no greater than 6 weeks prior to study registration. Biopsy of brain metastasis is not required. A patient may be enrolled with zero brain metastasis assuming that the SRS is to be directed at the post-operative surgical cavity of a resected metastasis. * Patients must be eligible to have all lesions treated with stereotactic radiosurgery as determined by the study radiation oncologist * Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital * Patients should have normal coagulation \[International Normalized Ratio (INR) \< 1.3\]. within 28 days of enrollment. * Patient's primary language is English * No prior radiation therapy to the brain, including WBRT, PCI, or SRS * Performance Status Assessment * Standard ECOG performance status assessment will be used and determined by the treating physician Exclusion Criteria: * Patients are excluded if they have a history of metastatic cancer in addition to small cell malignancy or a history of uncontrolled non-metastatic cancer. Patients with localized squamous cell carcinoma and/or basal cell carcinoma are not excluded * Patients are excluded if there is radiographic evidence of leptomeningeal disease * Patients are excluded if there are malignant cells identified in the CSF on cytologic examination * Patients are not excluded for circulating tumor deoxyribonucleic acid (DNA) (ctDNA) found in the CSF * Female patients of childbearing age are excluded if they are pregnant as determined with a urine or serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breast-feeding * Patients are excluded if they are unable to obtain an MRI scan for any other reason, including gadolinium allergy * Patients are excluded with medical history of a psychiatric or neurologic illness, or other comorbidities believed to affect cognitive function. Subjects with neurocognitive deficit related to brain metastasis are an exception to this criterion and may qualify for the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic lung small cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a memory drug and precision radiation save thinking during brain cancer treatment?
- Can we predict and treat cancer wasting better? a new study investigates
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Can a Chemo-Immunotherapy duo outsmart tough lung cancer?
- Wheat germ supplement studied for immune boost in advanced cancer
- New imaging agent may help doctors see which lung tumors are still growing during immunotherapy